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ABSTRACT 
Cerebral stroke is the principal reason of death without effective treatment in the world and recognized as the common cause of 
disability. Argyreia speciosa (Linn.f.) (Convolvulaceae, Synonyms: Argyreia nervosa) is widely distributed plant species in India. It is 
commonly known as Elephant creeper and Vryddhadaru. A. speciosa is a very valuable plant in the Ayurvedic system. In 'Rasayan' 
drug it has been used for the treatment of various neurological diseases. Its root taste is bitter and having the multiple uses like as a 
brain tonic, nootropic, anti-anxiety and anticonvulsant activity. The current study, plan to investigate the neuroprotective effect of 
ethanolic extract of A. speciosa root (ASEE) in a validate rat model of stroke known as global cerebral ischemic reperfusion injury 
(GCIRI). We divided 36 male Wistar rats to six experimental groups (n= 6). The group-I considered as sham control (no GCIRI), 
Group-II saline treated GCIRI, Group-III, IV, and V received ASEE (100, 200 and 400 mg/kg, p.o.) for 7 days prior to the induction of 
GCIRI while Group-VI termed as standard and it received quercetin (20 mg/kg, i.p.) 30 min prior induction of GCIRI. GCIRI produced 
the significant neurological deficit, sensorimotor dysfunction, decrease neurobehavioral parameters, increased cerebral infarction 
area and brain edema as compared with sham control rats. Seven days of pretreatment with ASEE markedly attenuates all the 
changes caused by GCIRI to the normal level. Our results proved that ASEE possess the protective effect on GCIRI induced stroke and 
aforementioned neuroprotection may be due to its antioxidant and anti-inflammatory property. 
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Stroke is listed in the second position between all the life-
threatening diseases and estimates for almost 11% of total 
deaths globally. It severely impairs the condition of life of 
the patient and further makes the enormous financial 
burden on the family and community1, 2. Stroke holds the 
fifth leading factor in mortality amongst people aged the 
periods of 15-59 years and the second important reason 
for death more than 60 years3. As the focus of brain tissue 
experiences necrotic cell destruction within a few minutes 
of the incipience of ischemic stroke, initial restoration of 
blood reanalyzed with thrombolytic minimizes morbidity 
and fatality in stroke subjects4. Nevertheless, that can be 
practiced hardly in maximum 5% of the stroke cases due to 
its short therapeutic time window and critical difficulties 
for therapy5. 
The etiology of ischemic-reperfusion injury (IRI) remains 
complicated, furthermore implicated in the interaction of 
many pathophysiological fashions. Oxidative stress 
performs a significant role in the overall pathogenesis of 
IRI6. Extreme reactive oxygen species (ROS) may upset the 
equilibrium between their generation and scavenge in the 
neuronal tissues, and they can offer quickly initiation of 
apoptotic and necrotic processes through a number of ion 
channels in ischemic-reperfused organ/tissue7. 
In addition cerebral ischemia triggers multiple cascades of 
pathophysiological effects including excitotoxicity, 
oxidative stress, leukocytes infiltration, calcium overload, 
inflammation, and apoptosis8. 
According to WHO and the results of various clinical 
investigation reveals that synthesized drugs remains 
usually challenging to attain desirable results because of 
severe adverse effects and single therapeutic target9,10. 
Hence, it is required to investigate more efficient drug with 
minimal adverse effects to treat the cerebral ischemia-
reperfusion, induced injury. 
A. speciosa is widely distributed plant species in India. It is 
commonly known as Elephant creeper, Samundar ka pat 
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and Vryddhadaru. It is found throughout in India up to 
altitude of 300-500 m. It is great climber with big ovate-
cordate leaves found growing native in north-eastern 
Himalaya, Dehradun, Konkan, Rajasthan, Mysore, and 
Bengal11. 
A. speciosa is a very valuable plant in the Ayurvedic system. 
In 'Rasayan' drug it has been used for the treatment of 
various neurological diseases.  
Its root taste is bitter and having the multiple uses like as a 
brain tonic, diuretic, aphrodisiac, rheumatism. In other 
hands for persistent cold & cough, and in resulting fever, 
root paste with Grewia hirsute, Asparagus racemosus and 
Hemidesmus indicus prescribed for immediate relief. 
Its seven times root powder is macerated throughout 7 
days with tubers juice of Asparagus racemosus as nervine 
tonic. It promotes intellect, strengthens body and 
counteracts influences of age. In addition one of its 
preparation known as Ajmodadi Churna used for unilateral 
paralysis, dysentry and rheumatic ailments12,13. 
A. speciosa contains various chemical constituents such as 
alkaloids (mainly ergoline), flavonoids, lipids, 
triterpenoids, saponin and steroids. The seeds mainly 
consisted of various fatty oils such as palmitic glycosides, 
stearic, oleic, linoleic and linolenic acid14. 
Principally roots contain the tetradecanyl palmitate, stigma 
steryl p-hydroxy cinnamate, hexadecanyl p-hydroxy 
cinnamate, quercetin and caffeic acid. Recently 6-methoxy 
coumarin-7-O-α-D-glucopyranoside (coumarin glucoside) 
also isolated by the researchers15. 
The phytochemical investigation revealed the presence of 
kaempferol, quercetin, kaempferol  
3-O-L-rhamnopyranoside, 7, 8, 3′, 4′, 5′-penta hydroxyl 
flavone and 5-O-β-D-glucopyranoside in A. speciosa 
leaves16. 
A. speciosa possess various pharmacological activity such 
as wound healing activity17, aphrodisiac activity18, 
hepatoprotective activity19 analgesic and anti-
inflammatory activity20,21, antidiabetic activity22, antiviral 
activity23, antiulcer activity24. 
In addition A. speciosa also posses various neurological 
property such as nootropic activity, anticonvulsion 
activity25,26, central nervous system depressant activity27.    
The abovementioned literature survey exhibits that A. 
speciosa possesses many pharmacological properties 
including nootropic, anti-anxiety and anticonvulsant 
activity but no work has ever been carried-out to evaluate 
the protective effect of A. speciosa on the stroke or stroke-
related disorder. Hence, in the present study, we 
investigated the neuroprotective effect of root extract of A. 
speciosa on global cerebral ischemic reperfusion injury in 
rats. 
MATERIALS AND METHODS 
Chemicals 
Thiobarbituric acid (TBA), trichloroacetic acid (TCA), 
triphenyltetrazolium chloride (TTC), nitroblue tetrazolium 
(NBT), gallic acid and quercetin were purchased from 
Sigma Chemicals USA. All other solvents and chemicals 
used in study were analytical grade. 
Plant materials 
The roots of A. speciosa were obtained from local market of 
Gwalior. The roots were authenticated by research officer 
of the Regional Ayurveda Research Institute for Drug 
Development, Gwalior, Madhya Pradesh. A voucher 
specimen No.5-4/17-18/RARIDD-Gwl/Tech/Survey/999 
was submitted to institute.  
Preparation of ethanolic extract of A. speciosa 
The roots were clean with water, cut in small parts and air 
dried then with the help of an electrical grinding machine 
to get coarsely powdered. For removing the various fatty 
materials, powdered root was extracted with petroleum 
ether in Soxhlet extractor at least for 24 h. The marc was 
subsequently macerated with ethanol to obtain an 
ethanolic extract. Extract was concentrated in a rotating 
evaporator and stored (airtight container) in the 
refrigerator for experimental used. The yield of the 
obtained extract was 11% (w/w) and termed as ASEE. 
Phytochemical analysis of ASEE 
Phytochemical screening was done to assess the presence 
of alkaloids, phenolic compounds, flavonoids, 
triterpenoids, coumarin, caffeic acid, carbohydrates, 
tannins, saponin, proteins, and steroids in ASEE as per 
approved methods28. 
Determination of total phenolic and total flavonoid 
content 
Total phenolic content of the ASEE was assessed using the 
spectrometric method given by Slinkard and Singleton29 
and expressed in terms of gallic acid equivalent (mg/g of 
extract) while total flavonoid content was estimated 
through aluminum chloride30 (colorimetric method) and 
expressed in term of quercetin equivalents (mg/g of 
extract). 
Animals 
Male (adult & Healthy) Wistar rats (220 g to 250 g) 
obtained from the animal house of the Jiwaji University, 
Gwalior. Rats remained transparent cage in the adequately 
vented room, maintained in 12-12 h (light/dark cycle) and 
were housed at 25°C ± 2°C temperature. All rats had easy 
entrance to a standard nutritional diet and water ad 
libitum. The experimental protocol was approved by IAEC 
(IAEC/JU/16). All the experimental surgery was conducted 
in accordance with the CPCSEA. 
Preliminary acute oral toxicity study 
Healthy Wistar rats (adult male, 220 to 250 g) were taken 
to acute oral toxicity studies and done as per the 423 
guidelines recommended by the Organization for Economic 
Co-operation and Development (OECD: 2001). Firstly we 
have taken overnight fasted 3 rats then the single oral dose 
(2000mg/kg) of ASEE given for the limit test, and carefully 
observed over 14 days for any death, behavioral and 
neurological alterations. 
Induction of global cerebral ischemic reperfusion 
injury (GCIRI) 
GCIRI was caused by occlusion of the bilateral common 
carotid artery (BCCA) as the surgical technique described 
earlier31. Overnight fasted rats were anesthetized under 
pentobarbital sodium (30 mg/kg, i.p.). To induce the 
cerebral ischemia, the individual common carotid artery 
was temporarily blocked for the period of 30 min with the 
help of bulldog clamp. Consequently, bulldog clamps were 
carefully withdrawn to permit reperfusion for 24 h to 
produce GCIRI. Sham-operated rats treated as a similar 
way, without blocking of BCCA. 
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Following reperfusion period, neurological deficit score, 
sensorimotor function, behavioral parameters were 
evaluated and lastly, the animals were ethically sacrificed 
by decapitation method for the evaluation of cerebral 
infarction size and brain water content. 
Experimental design 
Male Wistar rats (220 g-250 g) were separated into six 
groups (n=6) and administered with ASEE or normal saline 
for 7 days prior to GCIRI and treated as follows: 
Group I Sham control given normal saline orally (10 ml/kg 
for 7 days) 
Group II Ischemic reperfused group, GCIRI induced by 
blocking of BCCA for 30 min, followed by reperfusion for 
24 h 
Group III ASEE (100 mg/kg, orally for 7days) followed 
GCIRI 
Group IV ASEE (200 mg/kg, orally for 7days) followed 
GCIRI 
Group V ASEE (400 mg/kg, orally for 7days) followed 
GCIRI 
Group VI Received standard drug (quercetin: 20 mg/kg, i.p. 
given half hour before induction of GCIRI)
 
 
Figure 1: Schematic representation of experimental design.  
 
Neurological deficit scoring 
For the assessment of neurological deficit scoring, we 
adopted a four-point scale method, which was reported 
earlier32. As per our study design after causing GCIRI we 
determined the neurological deficit scoring through an 
evaluator who was masked to experimental plan. 
The neurological results were scored and recorded as 
followed:  
0: normal movement and absent of neurological deficit  
1: the obstacle to fully expanding of right paw   
2: circling movement toward the right side 
3: falling toward the right side 
4: problem to walk spontaneously and reduced the 
consciousness 
Evaluation of sensorimotor performance   
Hanging wire test 
After completion of the treatment plan, the rats were 
evaluated for their sensorimotor function and grip 
strength. For that, rats were suspended through its 
forelimbs on a thin metal wire, which pulled between two 
pillars, 60 cm over foam bedding. To stop the rat from 
using their hind limbs both are comfortably covered by 
adhering band. The duration of the period in seconds (s), 
until the rat fell down on the foam bedding, was recorded33. 
Rotarod test 
The sensorimotor performance of rats was assessed using 
a rotarod experiment. In this test firstly we have taken the 
pre-training trials of rats for reducing the dominance 
influence of learning ability. The pre-training assured the 
steady baseline performance on rotarod. All rats from 
different groups were examined for their ability to endure 
on the rotating metal rod at a accelerating speed of 10-30 
rpm. At last, Latency to fall off (s) from the rotating rod was 
noted with a 3 min cut off time34. 
Assessment of neurobehavioral parameters 
Open-field test 
The locomotor and anxiety activity of rat was assessed 
through an open field apparatus. It made up from a wooden 
pli-board, in the square shape box (96 × 96 × 50 cm). In 
addition, the basement of the box was separated into equal 
16 squares. The whole experimental room beside the open 
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field apparatus was retained dark throughout the test. 
While apparatus was lighted by a low 40 W bulb suspended 
100 cm over. Individually rat from different groups was put 
in any one corner of the open field. After it, we carefully 
observed rats for 5 min for ambulation (number of squares 
crossed), number of rearing, grooming, and fecal pellets35. 
Elevated plus maze 
Anxiety behavior in rats was evaluated by Elevated plus-
maze apparatus. It consisted of the central platform (5 cm x 
5 cm) that attached to two open arms (25 cm x 5 cm) 
intersect two enclosed arms (25 cm x 5 cm x 20 cm). The 
entire maze was elevated 50 cm above from the room floor. 
At the starting of the experiment, rat stayed put on the 
central platform seeing towards open arms. During 5 min 
of the observation period, we counted the total time spent, 
number of entries in the open arms and also evaluated the 
risk assessment behavior36. 
Evaluation of cerebral infarction area 
After the evaluation of sensorimotor function and 
neurobehavioral parameters, animals were subjected to 
the measurement of cerebral infarction (ischemic) area. 
The ischemic area was identified and measured by the TTC 
staining method37. Rats were sacrificed by decapitation 
method and very delicately brains were removed. Suddenly 
the brains were fixed in ice-cold saline and coronal brain 
sections of nearly 2 mm thickness were obtained. After 
that, the brain sections were incubated in normal saline 
containing 2% TTC for 30 min. The cerebral infarction area 
was noted and analyzed within sham-operated and treated 
rats. Cerebral infarction area was determined to apply the 
following formula: 
Cerebral infarction % = unstained (white) infarct area / 
section area × 100 
Estimation of brain edema (water content) 
Following decapitation, the rat's brains were quickly 
removed from the skull38. The brain, wet weights were 
estimated through an electrical balance, thereafter brains 
were dried oven at 100 °C for 24 h. Brain edema (water 
content) was computed using the following formula: 
Water content in the brain (%) = (wet weight − dry weight) 
/ wet weight× 100 
Statistical analysis 
All results were expressed as mean ± standard error of the 
mean (SEM). Statistical analyses were done using the 
statistical software Graph Pad Prism package, version 4.0. 
Differences between the sham-operated group and other 
treated groups were analyzed by one-way analysis of 
variance (ANOVA) followed by Tukey's comparison test. In 
addition, the scoring of neurological deficit was analyzed 
by employing a Kruskal-Wallis test followed by Dunn’s 
multiple test. After analysis, if we obtained the P < 0.05 




Phytochemical analysis of ASEE showed the occurrence of 
alkaloids, phenolic compounds, flavonoids, triterpenoids, 
coumarin, caffeic acid, carbohydrates, tannins, saponin, 
proteins, and steroids. 
 
Determination of total phenolic and total flavonoids 
content in ASEE 
The total phenolic and total flavonoid content was 
estimated to be 102 mg gallic acid equivalents/g of the 
extract, and 65.4 mg quercetin equivalents/g of the extract 
respectively. 
Present doses of ASEE holds no adverse effects to rats 
After evaluating the acute oral toxicity test we found that 
tested animals exhibited an absence of any toxic response, 
no abnormal change in body weight, behavior or 
death/moribund state up to the endpoint of the study. 
ASEE was seen to be safe up to 2000 mg/kg of dose (limit 
test) and approx LD50 was more than 2500 mg/kg. 
ASEE improves the neurological deficit score in GCIRI 
rats 
The statistical differences were found in neurological 
deficit scoring between the sham-operated group, GCIRI 
group and ASEE/standard treated groups, as depicted in 
Fig.2. GCIRI caused the rise in the neurological scoring (p < 
0.001) compared to sham rats. The neurological deficit had 
low scores in ASEE pretreatment animals at the dose of 
100, 200 and 400 mg/kg and quercetin-treated groups at 
the dose of 20 mg/kg (p < 0.05), compared with GCIRI. 
 
Figure 2: Effect of ASEE on neurological deficits. Results 
are expressed as mean ± SEM, n = 6.    *p < 0.001 when 
compared to sham control group; $p < 0.05, @p < 0.01 and 
#p < 0.001 when compared to GCIRI group. 
ASEE promotes the sensorimotor function and rotarod 
performance of GCIRI rats 
Fig. 3 shows the results of the effect of ASEE on 
sensorimotor performance. The grip strength on the 
hanging wire test was significantly lower (p < 0.001) in 
GCIRI rats when compared with the sham control rats. 
Pretreatment with ASEE (200, 400 mg/kg) and quercetin 
20 mg/kg statistically (p < 0.05- p < 0.001) increased the 
time spent while the lower dose (100 mg/kg) of ASEE 
failed to show significant response when compared with 
GCIRI rats. Pretreatment with ASEE (100, 200 and 400 
mg/kg) and quercetin dose-dependently improved their 
rotarod performance compared to GCIRI rats (Fig. 4). 
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Figure 3: Effect of ASEE on sensorimotor function (hanging 
wire test). Results are expressed as mean ± SEM, n = 6. *p < 
0.001 when compared to sham control group; $p < 0.05, @p 
< 0.01 and #p < 0.001 when compared to GCIRI group. 
 
Figure 4: Effect of ASEE on sensorimotor performance 
(rotarod test). Results are expressed as mean ± SEM, n = 6. 
*p < 0.001 when compared to sham control group; $p < 
0.05, @p < 0.01 and #p < 0.001 when compared to GCIRI 
group. 
 
ASEE improves the neurobehavioral parameters 
Open-field test 
GCIRI rats showed significant changes in locomotor 
activities in open field test (Table 1). GCIRI reduced the 
number of ambulation (p <0.001) and an increase in the 
period of immobility (P <0.001) when compared to control 
rats. In addition, GCIRI showed no changes in the value of 
rearing, grooming and fecal pellets. ASEE pretreatment 
significantly abolished the above alterations at dose level 
of 200 and 400 mg/kg (p < 0.05 - p <0.001). Standard drug 
pretreated rats also reverse the GCIRI induced changes (p 
<0.001).
 
Table: 1 Effect of ASEE on open-field behavior in animals subjected to GCIRI 
Treatment  Number of squares 
crossed 






Number of fecal 
pellets 
Sham Control 59.41 ± 3.32 98.78 ± 4.67  19.23 ± 1.56 6.26 ± 0.67 5.23 ± 0.52 
GCIRI 30.71 ± 3.72* 135.80 ± 6.12* 23.15 ± 2.65 8.53 ± 0.84  4.42 ± 0.44 
GCIRI+ ASEE100 46.61 ± 3.86 121.32 ± 6.71 25.54 ± 1.32 7.63 ± 0.74 5.52 ± 0.47 
GCIRI + ASEE200 50.24 ± 3.41$ 100.66 ± 6.51@ 21.52 ± 1.66 7.53 ± 0.56 5.76 ± 0.63 
GCIRI + ASEE400 53.84 ± 3.76@ 96.50 ± 4.19# 17.1 ± 1.72 7.33 ± 0.42 5.82 ± 0.42 
GCIRI + Quercetin 57.68 ± 4.34# 97.43 ± 4.28# 15.57 ± 1.21 7.26 ± 0.72 5.42 ± 0.44 
Values are in mean ± SEM, n = 6. *p < 0.001 when compared to sham control group; $p < 0.05, @p < 0.01 and #p < 0.001 when compared to 
GCIRI group. 
Elevated plus maze 
The outcomes from the elevated plus maze were also 
appreciated (Table 2). We found that there was a 
significant brain injury caused by GCIRI in rats, which 
confirmed through the significant reduction (p < 0.001) 
showed in the number of entries, time spent in open arms 
and the total arm entries when compared to the sham 
group. Moreover, rats also exhibited the significantly 
increased risk assessment behavior in GCIRI group (p < 
0.001). ASEE (100, 200 and 400 mg/kg) pretreated rats 
significantly regained their normal behavior with dose-
dependently (p < 0.05-p < 0.001). Quercetin also 
statistically (p < 0.001) reverse the alterations caused by 
GCIRI.
  
Table: 2 Effect of ASEE on elevated plus maze test in animals subjected to GCIRI 
Treatment Number of open arms 
entries 
Number of total arms 
entries 




Sham Control 15.27 ± 1.24 26.45 ± 2.6 57.19 ± 3.4 4.87 ± 0.51 
GCIRI 8.5 ± 0.81* 11.65 ± 1.16* 32.21 ± 2.5* 14.21 ± 1.68* 
GCIRI+ ASEE100 12.22 ± 0.74 18.16 ± 1.49 43.76 ± 3.26 11.58 ± 1.21 
GCIRI + ASEE200 13.10 ± 0.86$ 19.35 ± 1.18$ 49.63 ± 2.66@ 9.12 ± 0.75@ 
GCIRI + ASEE400 13.97 ± 0.75@ 21.19 ± 1.12@ 56.32 ± 3.20# 7.59 ±0.59# 
GCIRI + Quercetin 14.45 ± 0.81# 24.13 ± 1.61# 60.72 ± 3.44# 4.63 ± 0.38# 
Values are in mean ± SEM, n = 6. *p < 0.001 when compared to sham control group; $p < 0.05,         @p < 0.01 and #p < 0.001 when compared to 
GCIRI group. 
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ASEE reduces cerebral infarction area and brain 
edema 
GCIRI produced the significant (p < 0.001) increases in 
cerebral infarction (ischemic) size and brain water content 
when compared with the sham group (Fig. 4 & 5). Seven 
days pretreatments with ASEE (100, 200 and 400 mg/kg) 
markedly attenuated the edema in the brain and also 
diminished the ischemic area by 25.34%, 20.61%, 17.45% 
and standard drug, quercetin considerably lower infarct 
area by 17.10% and brain edema (p < 0.001) when 
compared to the GCIRI group. 
 
Figure 5: Effect of ASEE on brain infarction (TTC staining). 
Results are expressed as mean ± SEM, n = 3. *p < 0.001 
when compared to sham control group; $p < 0.05, @p < 0.01 
and #p < 0.001 when compared to GCIRI group. 
 
Figure 6: Effect of ASEE on brain edema (water content). 
Results are expressed as mean ± SEM, n = 3. *p < 0.001 
when compared to sham control group; $p < 0.05, @p < 0.01 
and #p < 0.001 when compared to GCIRI group. 
 
DISCUSSION 
In the present study, we described the neuroprotective 
effect of root of Argyreia speciosa against oxidative 
damages following global cerebral ischemic reperfusion 
injury in rats.  
In this current study, results surely indicate that 7 days 
pretreatment of ASEE and quercetin (standard) treatment 
shifted the neurological deficit, sensorimotor function, 
neurobehavioral parameters to the normal level and 
reduced the cerebral infarct area and brain water content 
(edema), in GCIRI group. For the induction of stroke, we 
selected well established global cerebral ischemic 
reperfusion model of rats. In this model, we blocked both 
common carotid arteries by bulldog clamp for half an hour 
followed by 24 h of reperfusion. 
GCIRI can be distinguished by two-phase: the early, 
primary brain tissue injury which initiated through 
ischemia following the subsequent tissue damage caused 
by reperfusion phase39. Presently all WHO approved drugs 
mainly targeted the initial phase (ischemic) of brain injury 
and reanalyzed the blocked blood vessels through 
thrombolytic action. But, they ineffective to cure the 
damage caused by the consequent reperfusion phase. It 
was also proved that reperfusion mainly responsible for 
brain tissue edema and hemorrhagic alteration, which may 
moreover worsen the cerebral ischemic injury40. Hence, 
GCIRI induced subsequent brain injury may assist as a 
target for the stroke-related disorder. Excitotoxicity, 
oxidative stress, excess free radicals, and neuro-
inflammation are the leading contributors to the 
pathogenesis of GCIRI41.  Brain tissues are highly sensitive 
to oxidative stress due to the immense consumption of 
oxygen molecules, the large quantity of polyunsaturated 
fatty acids and moderate levels of endogenous 
antioxidants. During GCIRI, the formation of free radicals 
has been very high which could conquer the antioxidant 
capability of the ischemic/reperfused brain42. During GCIR, 
lack of cerebral blood flow appears in a deprivation of 
various nutrients and oxygen supply to brain tissue that 
immediately begins to neurological dysfunction43. It was 
proved by many researchers that natural antioxidants give 
promising results in stroke and related disorders. For 
example, hexahydrocurcumin, Canna indica, Danshen, 
quercetin, and vitamin E attenuate cerebral ischemic 
reperfusion injury in animals through antioxidants 
activity44,45,46. 
In addition, antioxidants also give beneficial effects in 
numerous clinical studies conducted on the human. 
Hirvonen and colleague proved that diet enriched with 
antioxidants decreases the risk for brain infarction in male 
subjects47. Likewise, the moderate activity of antioxidant in 
blood is linked with prominent lesion area followed by 
neurological dysfunction in stroke patients48,49. Brought 
collectively, these outcomes recommend that antioxidant 
agents decrease the ischemia-reperfusion mediated injury 
in the brain. 
In the present study 7 days of pretreatment with 100, 200 
and 400 mg/kg of ASEE in GCIRI rats improved the 
neurological deficit score and support the earlier 
investigations. In addition, ASEE also reduced the 
infarction area and brain water content in GCIRI group in a 
dose-dependent way. Stroke model of GCIRI used for the 
cerebrovascular ischemic condition,  grey and white matter 
damage, loss of sensorimotor function, neurobehavioral 
dysfunction, optical fiber injury, diminished speech, 
anxiety and loss of memory50,51,52. It is well recorded that 
cerebral ischemia responsible for the impairment in 
sensorimotor performance and neurobehavioral 
function53,54. We used hanging wire test and rotarod test in 
the present study to evaluate the effect of GCIRI on 
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sensorimotor performance. Furthermore, hippocampal 
neurons are extremely sensitive to GCIRI and play an 
important role in anxiety, locomotor and learning 
process52. Hence, in the current study, we employed an 
open field test and elevated plus maze test to assess 
impairment in locomotion and anxiety caused by GCIRI. 
Seven days pretreatment of ASEE in GCIRI group 
significantly prevents the sensorimotor incoordination, 
neurobehavioral dysfunction and supports the earlier 
findings51,55. ASEE, standardized on the basis of total 
phenolic and flavonoid content and it was estimated to be 
102 mg gallic acid equivalents/g of the extract, and 65.4 
mg quercetin equivalents/g of the extract respectively. A. 
speciosa contains various chemical constituents such as 
alkaloids (mainly ergoline), flavonoids, lipids, 
triterpenoids, saponin and steroids. Principally roots 
contain the tetradecanyl palmitate, stigma steryl p-hydroxy 
cinnamate, hexadecanyl p-hydroxy cinnamate, quercetin 
and caffeic acid. Recently 6-methoxy coumarin-7-O-α-D-
glucopyranoside (coumarin glucoside) also isolated by the 
researchers15. 
It’s well documented that flavonoids and polyphenolics 
compounds play the vital role to prevent the stroke and 
related disorder. Root of A. speciosa rich with quercetin, 
caffeic acid and coumarin. Many investigators claim that 
quercetin possesses the anti-stroke activity55,56,57. Apart 
from this, coumarin and its derivatives compounds also 
attenuated the cerebral ischemic/reperfusion injury58,59,60. 
Whereas caffeic acid shown its neuroprotection via LOX 
and potent antioxidant activity52,61. These 
phytoconstituents have been shown to hold strong free 
radical scavenging activity, anticoagulants activity, 
antioxidant and anti-inflammatory activity. 
 Hence, quercetin, caffeic acid, and coumarin might be 
accountable for the perceived neuroprotection against the 
GCIRI. Our findings recommend that ethanolic extract of A. 
speciosa root revealed the statistically significant 
ameliorative impact on global cerebral ischemic-
reperfusion injury. 
CONCLUSION 
In conclusion, our investigations have shown the 
neuroprotective effects of ASEE against GCIRI induced 
brain damage, which was confirmed through turned the 
neurological deficit, sensorimotor function, 
neurobehavioral parameters to the normal level and 
reduced the infarct area and brain water content (edema), 
in GCIRI group. These results strongly suggest that ASEE is 
a possible supporting drug for the treatment of stroke or 
the related disorder. 
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